Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Oryzon Genomics S.A. (ORN.F)

Compare
2.7050
-0.0400
(-1.46%)
At close: April 17 at 8:08:41 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ORN.F

Recent News: ORN.F

View More
ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
GlobeNewswire 3 days ago
High Growth Tech Stocks In Europe March 2025

High Growth Tech Stocks In Europe March 2025
Simply Wall St. 30 days ago
European Growth Companies With High Insider Ownership To Watch

European Growth Companies With High Insider Ownership To Watch
Simply Wall St. 30 days ago
ORYZON to Provide Corporate Progress Updates at Several Events in March-April

ORYZON to Provide Corporate Progress Updates at Several Events in March-April
GlobeNewswire last month
Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat

Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
GlobeNewswire last month
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
GlobeNewswire last month
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting

ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting
GlobeNewswire last month
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024
GlobeNewswire last month
ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences

ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
GlobeNewswire 2 months ago
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting

ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting
GlobeNewswire 2 months ago
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome

ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
GlobeNewswire 2 months ago
View More